Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd (INDSWFTLAB) last reported results for the quarter ended Jun 2026, with sales of ₹191 crore and net profit of ₹25 crore. The stock last traded at ₹391, a market capitalisation of ₹3,400 crore, on a P/E of 52.2. Over the past 52 weeks the stock has ranged between ₹87 and ₹425. Figures are as of 6 Oct 2026 and are not real time.
Ind-Swift Laboratories Ltd share price and key metrics
- Current price
- ₹391
- Market cap
- ₹3,400 cr
- Stock P/E
- 52.2
- Book value
- ₹159
- ROE
- 4.02%
- ROCE
- 4.86%
- Dividend yield
- 0.00%
- 52w high / low
- 425/87.0
Metrics as of 6 Oct 2026. Not real time.
Track Ind-Swift Laboratories Ltd
Cruxal reads every Ind-Swift Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Ind-Swift Laboratories Ltd growth and returns
- 10 Years
- 0%
- 5 Years
- -6%
- 3 Years
- -19%
- TTM
- 54%
- 10 Years
- 12%
- 5 Years
- 79%
- 3 Years
- -6%
- TTM
- 195%
- 10 Years
- 26%
- 5 Years
- 43%
- 3 Years
- 60%
- 1 Year
- 279%
- 10 Years
- 3%
- 5 Years
- 6%
- 3 Years
- 7%
- Last Year
- 4%
Ind-Swift Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹191 cr, up 24.8% from ₹153 cr a year earlier. Net profit was ₹25 cr, up 177.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 129 | 138 | 153 | 153 | 151 | 170 | 191 |
| Expenses | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 |
| Operating profit | -12 | -7 | -9 | 4 | 1 | 4 | 21 | 33 |
| OPM % | -99% | -5% | -7% | 2.4% | 1.0% | 2.8% | 12% | 17% |
| Other income | 13 | 16 | 220 | 15 | 18 | 22 | -3 | 7 |
| Interest | 0 | 10 | -27 | 1 | 2 | 1 | -2 | 1 |
| Depreciation | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 |
| Profit before tax | 1 | -7 | 230 | 10 | 10 | 16 | 12 | 33 |
| Tax % | 31% | -16% | 4% | 17% | 22% | 42% | -26% | 25% |
| Net profit | 0 | -5 | 222 | 9 | 8 | 10 | 15 | 25 |
| EPS (₹) | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ind-Swift Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,281 | 574 | 649 | 665 |
| Operating profit | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 252 | -7 | 47 | 60 |
| OPM % | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 20% | -1.2% | 7% | 9% |
| Net profit | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 421 | 250 | 43 | 57 |
| EPS (₹) | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 71.24 | 41.32 | 4.97 | 6.73 |
TTM is the trailing twelve months to the most recent quarter.
Ind-Swift Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 59 | 69 | 87 |
| Reserves | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 872 | 1,104 | 1,297 |
| Borrowings | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 17 | 33 | 18 |
| Other liabilities | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 217 | 232 | 271 |
| Total liabilities | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,165 | 1,438 | 1,673 |
| Fixed assets | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 8 | 273 | 304 |
| CWIP | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 0 | 0 | 12 |
| Investments | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 111 | 213 | 248 |
| Other assets | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,047 | 952 | 1,110 |
| Total assets | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,165 | 1,438 | 1,673 |
As reported by the company. Total assets equal total liabilities by construction.
Ind-Swift Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 96 | 73 | -64 | 125 | 135 | 150 | 195 | -163 | -29 | -68 |
| Cash from investing | -31 | -17 | -12 | -9 | -10 | 5 | -13 | -104 | -113 | -69 |
| Cash from financing | -69 | -62 | 100 | -133 | -124 | -141 | -186 | 699 | 72 | 142 |
| Net cash flow | -4 | -6 | 23 | -17 | 1 | 14 | -4 | 431 | -69 | 5 |
| Free cash flow | 63 | 52 | -79 | 114 | 131 | 137 | 182 | -205 | -54 | -155 |
| CFO / operating profit | 90% | 54% | -51% | 87% | 73% | 74% | 85% | -65% | 323% | -131% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Ind-Swift Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% | 5% |
| Debtor days | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 105 | 112 |
| Inventory days | 305 | 291 | 284 | 313 | 301 | 288 | 242 | 6 | 145 | 187 |
| Days payable | 91 | 118 | 114 | 123 | 111 | 118 | 113 | 52 | 140 | 185 |
| Cash conversion cycle | 396 | 367 | 339 | 375 | 367 | 330 | 282 | 2 | 110 | 114 |
| Working capital days | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 115 | 156 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Ind-Swift Laboratories Ltd shareholding pattern
Promoters held 42.93% at Sep 2026, up from 39.49% at Sep 2025. FIIs 10.90% and DIIs 0.15%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.01% | 40.94% | 40.94% | 39.49% | 39.49% | 43.00% | 42.93% | 42.93% |
| FIIs | 0.46% | 3.07% | 4.27% | 14.80% | 14.33% | 13.88% | 10.70% | 10.90% |
| DIIs | 0.94% | 0.91% | 0.91% | 0.68% | 0.68% | 0.00% | 0.17% | 0.15% |
| Public | 56.61% | 55.08% | 53.88% | 45.02% | 45.50% | 43.14% | 46.19% | 46.01% |
| No. of shareholders | 28,752 | 28,117 | 28,709 | 43,780 | 42,121 | 39,222 | 40,881 | 42,112 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd corporate filings
- Ind-Swift Laboratories approves allotment of 14 lakh equity shares upon conversion of warrants, raising paid-up capital by ₹25 crore Corp Actionhigh impact
Cruxal's analysis: Ind-Swift Laboratories Limited announced the allotment of 14 lakh equity shares at ₹196…
Read the full analysis - Ind-Swift Laboratories announces newspaper publication regarding special window for relodgement of physical sharesCompany Updatelow impact
Cruxal's analysis: The company has issued a notice informing stakeholders about a special window for…
Read the full analysis - Ind-Swift Laboratories Announces AGM Voting Results and Board Re-appointments, with high approval for financials and director re-electionsAGM/EGMmedium impact
Cruxal's analysis: Ind-Swift Laboratories reported strong shareholder approval for its financial statements…
Read the full analysis - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please refer the attached pdf
Read the full analysis - Ind-Swift Laboratories Holds 31st AGM; No immediate financial disclosures or strategic announcements madeAGM/EGMlow impact
Cruxal's analysis: Ind-Swift Laboratories Limited conducted its 31st AGM on 30th September 2026 via video…
Read the full analysis - Ind-Swift Laboratories Ltd issues mandatory intimation regarding physical securities pursuant to SEBI circularCompany Updatelow impact
Cruxal's analysis: Ind-Swift Laboratories Ltd has issued a formal intimation to shareholders holding…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please refer the attached pdf.
Read the full analysis - Ind-Swift Laboratories schedules analyst/investor meet for September 29, 2026Company Updatelow impact
Cruxal's analysis: Ind-Swift Laboratories has announced an analyst and investor meeting scheduled for…
Read the full analysis - Ind-Swift Laboratories Limited: Promoter Group Acquires 70 Lakh Fully Convertible Warrants via Preferential IssueInsider Trading / SASTmedium impact
Cruxal's analysis: Ind-Swift Laboratories Limited has announced that the promoter group, led by Essix…
Read the full analysis - Ind-Swift Laboratories Limited: Promoter Group Acquires 70 Lakh Fully Convertible Warrants via Preferential IssueCompany Updatemedium impact
Cruxal's analysis: Ind-Swift Laboratories Limited has disclosed that its promoter group entity, Essix…
Read the full analysis - Ind-Swift Laboratories Limited Allots 70 Lakh Convertible Warrants to Promoter Group to Raise 34.30 CroreCompany Updatemedium impact
Cruxal's analysis: Ind-Swift Laboratories Limited has completed the allotment of 70,00,000 fully convertible…
Read the full analysis - Ind-Swift Laboratories Ltd: Routine Newspaper Publication of Financial/Corporate DisclosureCompany Updatelow impact
Cruxal's analysis: The company has filed a routine disclosure regarding the publication of a notice in…
Read the full analysis - Ind-Swift Laboratories Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Ind-Swift Laboratories has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Ind-Swift Laboratories Limited Announces 31st Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: Ind-Swift Laboratories Limited has issued a notice for its 31st Annual General Meeting…
Read the full analysis - Ind-Swift Laboratories Ltd publishes mandatory newspaper notice regarding Regulation 30Company Updatelow impact
Cruxal's analysis: The company has released a newspaper publication dated 04.09.2026 in compliance with…
Read the full analysis - Ind-Swift Laboratories Finalizes Preferential Issue Price for Warrants at INR 196 per shareCompany Updatemedium impact
Cruxal's analysis: Ind-Swift Laboratories Limited has formally set the issue price for its preferential…
Read the full analysis - Ind-Swift Laboratories Announces Board Appointments and 31st AGM ScheduleOtherslow impact
Cruxal's analysis: Ind-Swift Laboratories Limited has announced the appointment of Mr. Amit Mathur as an…
Read the full analysis - Ind-Swift Laboratories Ltd issues clarification regarding recent stock volume movementCompany Updatelow impact
Cruxal's analysis: The company has submitted a clarification to the stock exchange in response to a query…
Read the full analysis - Ind-Swift Laboratories Reports Strong Q1 FY27 Performance with 21% Revenue Growth and Margin ExpansionCompany Updatehigh impact
Cruxal's analysis: Ind-Swift Laboratories Limited delivered a strong Q1 FY27, with operating income growing…
Read the full analysis - Ind-Swift Laboratories targets 100 crore revenue increase from 2029-30 via Jammu facility upgradesCompany Updatemedium impact
Cruxal's analysis: Ind-Swift Laboratories has announced a strategic initiative to upgrade its Jammu…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.